Therapeutic Response

HER2-positive status confers therapeutic sensitivity to Capecitabine in patients with Adenocarcinoma of the Gastroesophageal Junction.

Statements

Source and description
Xeloda (capecitabine) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to capecitabine for the treatment of adult patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen.